Takeda Pharmaceutical (NYSE:TAK) Insider Sells 22,957 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Agosti Marcello Pignagnoli sold 22,957 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $392,564.70. Following the sale, the insider owned 176,977 shares of the company’s stock, valued at approximately $3,026,306.70. The trade was a 11.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.3%

TAK stock traded down $0.06 during mid-day trading on Wednesday, reaching $17.42. The company’s stock had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average price is $16.49 and its 200 day moving average price is $17.13. The company has a market cap of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. On average, equities research analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Takeda Pharmaceutical has an average rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of large investors have recently modified their holdings of TAK. Royal Bank of Canada grew its position in Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares during the period. AQR Capital Management LLC grew its holdings in shares of Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after buying an additional 59,442 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock worth $1,230,000 after acquiring an additional 3,239 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new position in Takeda Pharmaceutical in the 2nd quarter valued at about $351,000. 9.17% of the stock is currently owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.